TMEM45A is essential for hypoxia-induced chemoresistance in breast and liver cancer cells
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Background: Hypoxia is a common characteristic of solid tumors associated with reduced response to radio- and chemotherapy, therefore increasing the probability of tumor recurrence. The aim of this study was to identify new mechanisms responsible for hypoxia-induced resistance in breast cancer cells. Methods: MDA-MB-231 and HepG2 cells were incubated in the presence of taxol or etoposide respectively under normoxia and hypoxia and apoptosis was analysed. A whole transcriptome analysis was performed in order to identify genes whose expression profile was correlated with apoptosis. The effect of gene invalidation using siRNA was studied on drug-induced apoptosis. Results: MDA-MB-231 cells incubated in the presence of taxol were protected from apoptosis and cell death by hypoxia. We demonstrated that TMEM45A expression was associated with taxol resistance. TMEM45A expression was increased both in MDA-MB-231 human breast cancer cells and in HepG2 human hepatoma cells in conditions where protection of cells against apoptosis induced by chemotherapeutic agents was observed, i.e. under hypoxia in the presence of taxol or etoposide. Moreover, this resistance was suppressed by siRNA-mediated silencing of TMEM45A. Kaplan Meier curve showed an association between high TMEM45A expression and poor prognostic in breast cancer patients. Finally, TMEM45 is highly expressed in normal differentiated keratinocytes both in vitro and in vivo, suggesting that this protein is involved in epithelial functions. Conclusion: Altogether, our results unravel a new mechanism for taxol and etoposide resistance mediated by TMEM45A. High levels of TMEM45A expression in tumors may be indicative of potential resistance to cancer therapy, making TMEM45A an interesting biomarker for resistance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kim, J.-W., Tchernyshyov, I., Semenza, G. L., & Dang, C. V. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.02.002 · Cited by 3,905 · cited 2×
“The list of these genes included known hypoxia-responsive targets such as ALDOC [41], PFKFB4 [42], PDK1 [43], BNIP3 [44], NDRG1 [45], ENO2 [46], PFKFB3 [47] and JMJD1A [48].”
Targeting multidrug resistance in cancer
Szakács, G., Paterson, J. K., Ludwig, J. A., Booth-Genthe, C., & Gottesman, M. M. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd1984 · Cited by 3,609
Hypoxia in cancer: significance and impact on clinical outcome
Vaupel, P., & Mayer, A. (2007) · Cancer and Metastasis Reviews · doi:10.1007/s10555-007-9055-1 · Cited by 2,240
Evaluation of HIF-1 inhibitors as anticancer agents
Semenza, G. L. (2007) · Drug Discovery Today · doi:10.1016/j.drudis.2007.08.006 · Cited by 363 · cited 1×
“Hypoxia, the reduction of the normal level of tissue oxygen tension, is a common feature of solid tumors caused by of the abnormal vascular network and the high proliferation rate of cancer cells [10].”
Cosse, J.-P., & Michiels, C. (2008) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/187152008785914798 · Cited by 348 · cited 1×
“Tumor hypoxia is often associated with resistance to chemotherapy [7] and radiotherapy [8], with tumor progression, aggressiveness and metastasis, and therefore with an increased probability of tumor recurrence [9].”
Self-citationHelczynska, K., Larsson, A.-M., Holmquist Mengelbier, L., Bridges, E., Fredlund, E., Borgquist, S., Landberg, G., Påhlman, S., & Jirström, K. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1135 · Cited by 136 · cited 2×
“Indeed, HIF-1α [13] or HIF-2α [14] expression, as surrogate markers of tumor hypoxia, correlates with distant recurrence and poor outcome.”
Sullivan, R., & Graham, C. H. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-1090 · Cited by 65
Cited by
Role of hypoxia in cancer therapy by regulating the tumor microenvironment
Jing, X., Yang, F., Shao, C., Wei, K., Xie, M., Shen, H., & Shu, Y. (2019) · Molecular Cancer · doi:10.1186/s12943-019-1089-9 · Cited by 2,054
“In an HIF-1α-deficient cell model, the transcript levels of DNA–PK complex members, DNA– PKcs and Ku80, were downregulated, leading to a higher susceptibility to chemotherapeutics and introducing DNA double-strand breaks [35].”
BackgroundJarrar, Y., Zihlif, M., Al Bawab, A. Q., & Sharab, A. (2020) · Current Cancer Drug Targets · doi:10.2174/1568009619666191116095847 · Cited by 36
TMEM39A and Human Diseases: A Brief Review
Tran, Q., Park, J., Lee, H., Hong, Y., Hong, S., Park, S., Park, J., & Kim, S.-H. (2017) · Toxicological Research · doi:10.5487/tr.2017.33.3.205 · Cited by 25
“Indeed, TMEM45A is essential for hypoxia-induced chemo-resistance in breast and liver cancers (7).”
Background
Metadata
- Authors
- Flamant, L., Roegiers, E., Pierre, M., Hayez, A., Sterpin, C., De Backer, O., Arnould, T., Poumay, Y., & Michiels, C.
- Venue
- BMC Cancer
- Published
- 2012-09-06
- Volume
- 12
- Issue
- 1
- Pages
- 391-391
- ISSN
- 1471-2407 (ISSN-L)
- OpenAlex
- W2147754115
- Cited by
- 103
- References
- 7
- FWCI
- 1.32
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: TMEM45A is essential for hypoxia-induced chemoresistance in breast and liver cancer cells. https://app.cochat.ai/papers/10.1186/1471-2407-12-391
- The paper
- Flamant, L., Roegiers, E., Pierre, M., Hayez, A., Sterpin, C., De Backer, O., Arnould, T., Poumay, Y., & Michiels, C. (2012). TMEM45A is essential for hypoxia-induced chemoresistance in breast and liver cancer cells. BMC Cancer. https://doi.org/10.1186/1471-2407-12-391
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.